Kura Flat on Developments
Kura Oncology, Inc. (NASDAQ: KURA) shares fought doggedly ahead Wednesday. The San Diego-headquartered firm, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that an abstract containing preclinical data for KO-2806, the Company’s next-generation farnesyl transferase inhibitor (FTI), in combination with cabozantinib, a tyrosine […]
Kura Flat on Developments Read More »